Werbung ausblenden

News zu Celyad Oncology

Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial · Uhr · Business Wire
Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial · Uhr · Business Wire
Celyad Oncology Announces February 2022 Conference Schedule · Uhr · Business Wire
Celyad Oncology Provides Outlook for 2022 · Uhr · Business Wire
Celyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) · Uhr · Business Wire
Celyad Oncology Announces January 2022 Conference Schedule · Uhr · Business Wire
Celyad Oncology SA: Transparency Notification Received from Tolefi SA and Related Persons (Article 14 §1 of the Law of 2 May 2007) · Uhr · Business Wire
Transparency Notification Received From Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007) · Uhr · Business Wire
Celyad Oncology Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annual Meeting and Exposition · Uhr · Business Wire
Celyad Oncology Announces Closing of $32.5 Million Private Placement with Fortress Investment Group Affiliate · Uhr · Business Wire
Celyad Oncology Announces $32.5 Million Private Placement With Fortress Investment Group · Uhr · Business Wire
Celyad Oncology Presents Preclinical Data on Allogeneic CAR T Therapy Program and Highlights KEYNOTE-B79 Clinical Trial Design at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting · Uhr · Business Wire
Celyad Oncology Announces Third Quarter 2021 Financial Results and Recent Business Highlights · Uhr · Business Wire
Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 63rd ASH Annual Meeting and Exposition · Uhr · Business Wire
Celyad Oncology Announces November 2021 Conference Schedule · Uhr · Business Wire
Celyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) · Uhr · Business Wire